O
NBIX icon

Ossiam’s Neurocrine Biosciences NBIX Stock Holding History

Ossiam’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$177K Buy
1,342
+4
+0.3% +$531 ﹤0.01% 325
2025
Q4 		$190K Sell
1,338
-863
-39% -$125K ﹤0.01% 333
2025
Q3 		$309K Sell
2,201
-788
-26% -$107K ﹤0.01% 586
2025
Q2 		$376K Hold
2,989
– – ﹤0.01% 496
2025
Q1 		$331K Sell
2,989
-496
-14% -$62.8K ﹤0.01% 465
2024
Q4 		$476K Buy
3,485
+484
+16% +$59.9K 0.01% 462
2024
Q3 		$346K Buy
3,001
+2,912
+3,272% +$399K 0.01% 494
2024
Q2 		$12.3K Buy
+89
New +$12.2K ﹤0.01% 611
2024
Q1 		– Sell
-5,376
Closed -$708K – 665
2023
Q4 		$708K Buy
5,376
+614
+13% +$70.7K 0.01% 417
2023
Q3 		$536K Buy
4,762
+1,579
+50% +$166K 0.01% 455
2023
Q2 		$300K Buy
3,183
+1,834
+136% +$179K 0.01% 531
2023
Q1 		$137K Buy
1,349
+603
+81% +$62.7K ﹤0.01% 542
2022
Q4 		$89.1K Hold
746
– – ﹤0.01% 597
2022
Q3 		$79K Buy
+746
New +$75.7K ﹤0.01% 624

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ossiam's NBIX Position: Q1 2026 in Review

Ossiam increased its Neurocrine Biosciences (NBIX) stake by 0.3% in Q1 2026, buying an estimated $531 and bringing the position to 1,342 shares worth $177K. The position accounts for ﹤0.01% of the portfolio, ranked #325.

Ossiam first reported a position in NBIX in Q3 2022 and has held it in 14 quarters since. The position peaked at $708K in Q4 2023. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Ossiam held 1,342 shares of Neurocrine Biosciences worth $177K as of Q1 2026.
  • Ossiam bought 4 Neurocrine Biosciences shares in Q1 2026, an estimated $531.
  • Neurocrine Biosciences made up ﹤0.01% of Ossiam's portfolio in Q1 2026, its #325 holding.
  • Ossiam first reported a position in Neurocrine Biosciences in Q3 2022 and has held it in 14 quarters since.
  • Ossiam's Neurocrine Biosciences position peaked at $708K in Q4 2023.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Ossiam's 13F filing for Q1 2026, filed 14 May 2026.